BioLife Solutions, Inc.

BioLife Solutions, Inc.(BLFS)股票分析

$38.610

+1.355 (+3.51%)收盘时

Loading chart…
最高
38.830
开盘
37.160
成交量加权均价
38.13
成交量
4.45M
市值
944.41M
最低
36.950
成交额
169.53M
企业价值/息税折旧摊销前利润(TTM)
164.02

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

AI 分析 of BioLife Solutions, Inc. (BLFS)

持有

BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.

分析师评级(3)

-13.88% 下跌空间
买入
2 买入
1 持有
0 卖出
当前: 38.61
最低
32.00
平均
33.25
最高
34.00

Benchmark

2026-08-10

目标价

—

持有

Jefferies

2026-07-23

目标价

$31

持有

H.C. Wainwright

2026-07-23

目标价

$31

中性

TD Cowen

2026-07-22

目标价

$31

持有

Craig-Hallum

2026-07-22

目标价

$31

持有

估值指标

BioLife Solutions, Inc.(BLFS)当前预期市盈率为 238.10,5 年平均预期市盈率为 -160.78。

预期市盈率

合理
5 年均值 P/E
-160.78
当前P/E
238.10
高估
737.41
低估
-1058.97

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
78.44
当前EV/EBITDA
164.02
高估
193.73
低估
-36.86

预期市销率

高估
5 年均值 P/S
8.25
当前P/S
14.01
高估
11.34
低估
5.16

Alphio AI 对 BLFS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BLFS

$26.69

情景价格

基

基准

基准 · 50%BLFS

$21.52

情景价格

悲

悲观

悲观 · 25%BLFS

$21.37

情景价格

持有 BLFS 的大户

C

Cramer Rosenthal McGlynn LLC

+ 持有BLFS

-10.12%

3个月收益率

事件时间线

2026-10-05 (ET)

17:30:00

Repligen Acquires BioLife Solutions

2026-07-27 (ET)

08:00:00

Stephens Downgrades BioLife Solutions Price Target to $31

2026-07-22 (ET)

16:31:00

Major Averages Close Fractionally Lower as Traders Remain Cautious

15:00:00

Maxim Downgrades BioLife Solutions to Hold After Repligen's $31 Acquisition

12:30:00

Major Averages Mixed as Oil Prices Surge Again

资讯

BLFS 常见问题 —— 由 Alphio AI 解答

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.

3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易